to bone resorption and impending hypercalcemia, we chose patients with bronchogenic cancer who were normocalcemic initially for a pilot study. Surprisingly, we found that many of these normocalcemic patients had high calcitonin levek5 To characterize further the phenomena of hypercalcitonemia in bronchogenic cancer, we studied 28 patients.
reviously we have demonstrated that infusion of Pcalcium results in a significant increase in levels of serum calcitonin in normal man.I3 In addition, many patients with spontaneous hypercalcemia associated with various malignant neoplasms were also found to have high value^.^^' In order to study the natural history of calcitonin production in response to bone resorption and impending hypercalcemia, we chose patients with bronchogenic cancer who were normocalcemic initially for a pilot study. Surprisingly, we found that many of these normocalcemic patients had high calcitonin levek5 To characterize further the phenomena of hypercalcitonemia in bronchogenic cancer, we studied 28 patients.
Twenty-six men with bronchogenic cancer were studied during the past two years (Table 1 ). An attempt was made *From the Veterans Administration Hospital and George Washin on University School of Medicine, Washington, DC, a n f t h e National Institutes of Health, Bethesda to select normocalcemic patients whose clinical condition did not appear to be preterminal. The patients ranged in age from 42 to 82 years (mean, 56 years). In all cases the diagnosis had been proven by tissue examination (bronchoscopy, thoracotomy, or lymph node biopsy). The mean period of time between the initial diagnosis and the commencement of study was 20 days (range, two days to three months). There were 11 patients (42 percent) with smallcell cancer, seven (27 percent) with adenocarcinoma, six (23 percent) with epidermoid cancer, and two ( 8 percent) with large-cell cancer.
The senun calcium level was determined by atomic absorption spectrophotometry, and the ionic calcium level was measured by a specific electrode flow-through system.6 Senun phosphate and aJkaline phosphatase levels were measured by an automatic analyzer. The serum calcitonin level was measured by a radioimmunoassay developed in our laboratory.2~7 Briefly, human synthetic calcitonin monomer was conjugated with hematocyanin and injected with Freund's adjuvant into rabbits. The antibody ( Ab-I) which was obtained after six months of booster injections was used at a final dilution of 1:20,000. In the assay the serum, antibody, and labeled hormone are incubated at pH 7.5 for six to 14 days at 4 C , and bound and free hormone are separated by use of polyethylene glycol. The technique for infusion of calcium has also been described2 Two patients had selective retrograde venous catheterization of the thyroid venous effluent and of the venous drainage from the hunor, with subsequent analysis for calcitonin content.8 In all patients the presence of bone metastases was determined by radiographic survey of the bones, by radioisotopic scan, or by needle biopsy of the iliac crest and, when applicable, postr.,ortem examination of a section of vertebra.
Of the 26 patients, 23 have died. Twenty-two patients (85 percent) lived long enough to have more than one calcitonin determination, and 14 pa- tients (54 percent) had more than five detenninations. The initial mean level of serum calcium (+SD) at the onset of the study was 9.3 + 0.6 mg1100 ml ( range 7.9 to 10.3 mg/ 100 ml ) , and for ionic calcium was 4.9 & 0.2 mg/ 100 ml ( range, 4.4 to 5.4 mg/ 100 ml ). In all but four patients, the serum calcium level remained normal throughout the investigation.
The serum calcitonin values of the patients are shown in Table 1 . The range of normal is undetectable ( < 50 ppglml) to 340 ,.+g/ml; 95 percent of normal persons have levels less than 260 ppglrnl. The initial mean calcitonin level ( k SD) of the patients was 650 p+g/ml k 1,170 ppg/ml (range, 50 ppg/ml to 5,800 pPg/ml). Subsequently, the mean of the highest recorded calcitonin levels was 1,680 ppg/ml * 3,720 ppglml (range, 100 prg/ml to 16,000 p+g/ml) (Fig 1) . The significance of the difference between the mean of normal persons and that of both the initial and the highest values of the patients with bronchogenic cancer is P < 0.001. Arbitrarily designating all values above 400 pPg/ml as clearly abnormal, 42 percent of initial values and 62 percent of the subsequent peak values were elevated.
There were no statistically signscant correlations between serum calcitonin level and the levels of serum calcium, phosphate, or alkaline phosphatase. During the course of follow-up, 16 patients were found to have osseous metastases. Of those patients with high calcitonin levels (over 400 wglrnl), nine (56 percent) of 16 patients had osseous metastases; of those with normal levels, seven (70 percent) of ten had osseous metastases ( Fig 2 ) .
One of our patients (No. 8 ) who had small-cell carcinoma of the lung had an initial serum calcitonin level of 580 ppglml. Following chemotherapy, the 15,000
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peripheral calcitonin level had decreased to 50 +~pg/ rnl. At the time, percutaneous venous catheterization was performed. The thyroid venous effluent had a calcitonin level of 200 ppg/rnl, while the thymic vein, which was draining the tumor, contained 1,900 ppglml. Three months later, when catheterization was repeated, the thyroid effluent had a calcitonin level of 340 ppg/ml, and the thymic vein contained 5,400 ppglml. This patient has been reported previo u~l y .~ He is still alive and receiving maintenance chemotherapy, and has a normal peripheral calcitonin level. This patient represents the ectopic production of calcitonin. A second patient (No. 22), with adenocarcinoma of the lung, had an initial peripheral serum calcitonin level of 630 ppg/ml. Catheterization of the thyroid venous effluent revealed a calcitonin level of 4,100 ppglml, while catheterization of the right highest intercostal vein, which was draining tumor deposits, revealed only 400 ppg/ml.'O In contrast, this patient represents production of calcitonin by the thyroid gland.
We have reported that chemotherapy or x-ray irradiation of bronchogenic cancer may be associated with a striking drop in serum calcitonin l e~e l s .~. '~ In the present study, there were insufficient data to discern how frequently this phenomenon occurs. In addition to these two patients, we have had the opportunity to study several other patients sequentially. For example, during a period of eight months from initial diagnosis until death, we studied a 63-year-old man (No. 6 ) with metastatic adenocarcinoma of the lung who had an initial serum calcitonin level of 1,900 ppg/ml prior to therapy (Fig 3 ) . During treatment with x-ray irradiation, methotrexate and cyclophosphamide, the serum level of calcitonin gradually diminished to 520 ppg/ml. After increasing again to 1,800 pPg/rnl 2% months later, a second course of therapy was associated with a dramatic decrease in calcitonin level to 170 ppg/ml, remaining at normal levels for two months; however, immediately prior to the patient's death, the serum calcitonin level again had increased, reaching 16,000 ppgIm1. During his entire course, the patient remained normocalcemic, in spite of extensive skeletal metastases.
Determinations of serum levels of calcitonin obtained by retrograde venous catheterization have suggested two varieties of hypercalcitonemia: ( 1 ) ectopic hypercalcitonernia, in which the tumor is producing the calcitonin, and ( 2 ) thyroidal hypercalcitonemia, in which the thyroid gland is secreting the hormone. We do not know the relative incidence of ectopic as opposed to thyroidal hypercalcitonemia, since many of these patients were too ill to undergo catheterization and postmortem analysis of tumor tissue was not always performed.
We do not know the cause of thyroidal hypercalcitonemia in cancer. Is the thyroid gland secreting large amounts of calcitohin in an attempt to protect against hypercalcemia which would otherwise occur due to rapid metastatic or hurnoral bone resorption? In this study the incidence of clinically apparent metastases to bone was slightly lower in those patients with high calcitonin values; however, our patients did not have an extensive search for bone involvement at autopsy. Nevertheless, 70 percent of the patients who did, indeed, have metastases to bone had normal serum calcitonin levels. It is known that cancer can secrete hurnoral substances which cause bone resorption without the presence of and we do not know whether this phenomenon might play a role in inducing thyroid hypercalcitonemia.
In 1973 and 1974, weQ*l5 described the ectopic production of calcrtonin in two patients with bronchogenic carcinoma of the small-cell variety. Subsequently, this phenomenon has been co&rmed.l6.l7 Other investigators have noted elevated values of calcitonin in the serum or in the tumor tissue of various other nonthyroid can~ers.l'-~" Often, the tumor was of nervous tissue or originated from tissue which is believed to have been derived embryologically from neural ectoderm. In this regard, it is interesting that small-cell cancer has been postulated to arise from argentaffine cells which migrate from the neural ~r e s t .~l .~~ Embryologic evidence suggests that the C cells of the thyroid, which normally secrete calcitonin, are also derived from the neural crest,23 and the ectopic calcitonin production by the aforementioned tumors might reflect an interrelationship of their ectodermal precursor cells.g Nevertheless, Coombes and co-workerss reported that tumors of nonectodermal origin, such as those of the pancreas, maxillary antrum, prostate, uterus, bladder, and breast, also can be associated with high serum calcitonin values. These authors also studied 11 patients with small-cell bronchogenic cancer and noted hypercalcitonemia in eight. None of their four patients with epidermoid carcinoma had high serum calcitonin levels.
In the present study, we found hypercalcitonernia ( < 400 ppg/ml) in 62 percent (16 of 26 patients with bronchogenic cancer of various cells types. Although the number of patients is insufficient and the method of selection is invalid to draw definitive conclusions, the highest incidence of hypercalcitonemia was found in patients with small-cell cancer (nine of 11 patients) and adenocarcinoma (five of seven patients). Only two of six patients with epidermoid cancer had hypercalcitonernia. The highest serum level encountered was in a patient with adenocarcinoma.
Further studies are needed to determine the pathophysiologic mechanism of hypercalcitonemia in cancer and to elucidate whether serum calcitonin levels in neoplasia have diagnostic implications or can be of prognostic utility in the evaluation of therapy. Such a long-term study is underway in our laboratory.
